GATA-3 在 T 细胞淋巴增生性疾病中的作用。
GATA-3 in T-cell lymphoproliferative disorders.
机构信息
Department of Internal Medicine, Division of Hematology-Oncology, University of Michigan, Ann Arbor, Michigan.
出版信息
IUBMB Life. 2020 Jan;72(1):170-177. doi: 10.1002/iub.2130. Epub 2019 Jul 17.
Abstract
GATA-3 regulates the differentiation, proliferation, survival, and function of peripheral T cells and their thymic progenitors. Recent findings, reviewed here, not only implicate GATA-3 in the pathogenesis of molecularly, genetically, and clinically distinct T-cell lymphoproliferative disorders, but also have significant diagnostic, prognostic, and therapeutic implications.
摘要
GATA-3 调节外周 T 细胞及其胸腺前体细胞的分化、增殖、存活和功能。在这里综述的最新发现不仅表明 GATA-3 参与了分子上、遗传上和临床上不同的 T 细胞淋巴增生性疾病的发病机制，而且具有重要的诊断、预后和治疗意义。
相似文献
1
GATA-3 in T-cell lymphoproliferative disorders.GATA-3 在 T 细胞淋巴增生性疾病中的作用。
IUBMB Life. 2020 Jan;72(1):170-177. doi: 10.1002/iub.2130. Epub 2019 Jul 17.
2
GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features.GATA-3 表达鉴定出一组具有独特分子和临床特征的高风险、NOS 侵袭性 T 细胞淋巴瘤亚群。
Blood. 2014 May 8;123(19):3007-15. doi: 10.1182/blood-2013-12-544809. Epub 2014 Feb 4.
3
miRNA‑135a regulates Hut78 cell proliferation via the GATA‑3/TOX signaling pathway.miRNA-135a 通过 GATA-3/TOX 信号通路调节 Hut78 细胞增殖。
Mol Med Rep. 2019 Mar;19(3):2361-2367. doi: 10.3892/mmr.2019.9885. Epub 2019 Jan 22.
4
Biologic and clinical heterogeneity of lymphoproliferative diseases of peripheral mature T lymphocytes.外周成熟T淋巴细胞淋巴增殖性疾病的生物学和临床异质性。
Lab Invest. 1992 Sep;67(3):274-302.
5
[Imbalanced T cell-specific transcription factors T-bet and GATA-3 contributes to type 2 T helper cell polarization in asthmatic patients].[失衡的T细胞特异性转录因子T-bet和GATA-3促成哮喘患者2型辅助性T细胞极化]
Zhonghua Jie He He Hu Xi Za Zhi. 2004 Jun;27(6):398-402.
6
GATA-3 protects against severe joint inflammation and bone erosion and reduces differentiation of Th17 cells during experimental arthritis.GATA-3可预防实验性关节炎期间的严重关节炎症和骨侵蚀，并减少Th17细胞的分化。
Arthritis Rheum. 2009 Mar;60(3):750-9. doi: 10.1002/art.24329.
7
[Changes in the expression of three markers in T lymphocytes of peripheral blood and immunoregulatory mechanisms of burned mice with sepsis at early stage].[外周血T淋巴细胞中三种标志物表达变化及烧伤脓毒症小鼠早期免疫调节机制]
Zhonghua Shao Shang Za Zhi. 2016 Feb;32(2):89-96. doi: 10.3760/cma.j.issn.1009-2587.2016.02.007.
8
Expression of the transcription factor GATA-3 is required for the development of the earliest T cell progenitors and correlates with stages of cellular proliferation in the thymus.转录因子GATA-3的表达是最早的T细胞祖细胞发育所必需的，并且与胸腺中细胞增殖的阶段相关。
Eur J Immunol. 1999 Jun;29(6):1912-8. doi: 10.1002/(SICI)1521-4141(199906)29:06<1912::AID-IMMU1912>3.0.CO;2-D.
9
GATA-3 is a proto-oncogene in T-cell lymphoproliferative neoplasms.GATA-3 是 T 细胞淋巴增生性肿瘤中的原癌基因。
Blood Cancer J. 2022 Nov 4;12(11):149. doi: 10.1038/s41408-022-00745-y.
10
[Heterogeneity of T gamma-lymphoproliferative disorder-- case report and review of the literature].[Tγ淋巴细胞增殖性疾病的异质性——病例报告及文献复习]
Rinsho Ketsueki. 1986 Dec;27(12):2325-32.
引用本文的文献
1
The Progression of Mycosis Fungoides During Treatment with Mogamulizumab: A BIO-MUSE Case Study of the Tumor and Immune Response in Peripheral Blood and Tissue.莫加莫珠单抗治疗蕈样肉芽肿的病程：一项关于外周血和组织中肿瘤及免疫反应的BIO-MUSE病例研究
Biomedicines. 2025 Jan 14;13(1):186. doi: 10.3390/biomedicines13010186.
2
Unveiling GATA3 Signaling Pathways in Health and Disease: Mechanisms, Implications, and Therapeutic Potential.揭示健康与疾病中的GATA3信号通路：机制、意义及治疗潜力
Cells. 2024 Dec 22;13(24):2127. doi: 10.3390/cells13242127.
3
A20 haploinsufficiency disturbs immune homeostasis and drives the transformation of lymphocytes with permissive antigen receptors.A20 杂合性缺失扰乱免疫稳态，并驱动具有许可性抗原受体的淋巴细胞发生转化。
Sci Adv. 2024 Aug 23;10(34):eadl3975. doi: 10.1126/sciadv.adl3975. Epub 2024 Aug 21.
4
The role of deacetylase SIRT1 in allergic diseases.去乙酰化酶 SIRT1 在过敏性疾病中的作用。
Front Immunol. 2024 Jul 16;15:1422541. doi: 10.3389/fimmu.2024.1422541. eCollection 2024.
5
Transcription factor genetics and biology in predisposition to bone marrow failure and hematological malignancy.骨髓衰竭和血液系统恶性肿瘤易感性中的转录因子遗传学与生物学
Front Oncol. 2023 Jun 12;13:1183318. doi: 10.3389/fonc.2023.1183318. eCollection 2023.
6
ITK degradation to block T cell receptor signaling and overcome therapeutic resistance in T cell lymphomas.ITK 降解可阻断 T 细胞受体信号转导并克服 T 细胞淋巴瘤的治疗抵抗。
Cell Chem Biol. 2023 Apr 20;30(4):383-393.e6. doi: 10.1016/j.chembiol.2023.03.007. Epub 2023 Apr 3.
7
Genome-Wide Gene-Set Analysis Identifies Molecular Mechanisms Associated with ALS.全基因组基因集分析鉴定与 ALS 相关的分子机制。
Int J Mol Sci. 2023 Feb 16;24(4):4021. doi: 10.3390/ijms24044021.
8
Classification and challenges in the histopathological diagnosis of peripheral T-cell lymphomas, emphasis on the WHO-HAEM5 updates.外周T细胞淋巴瘤组织病理学诊断的分类与挑战，重点介绍世界卫生组织血液和淋巴组织肿瘤分类第5版更新内容
Front Oncol. 2022 Dec 20;12:1099265. doi: 10.3389/fonc.2022.1099265. eCollection 2022.
9
Transcriptome-wide subtyping of pediatric and adult T cell acute lymphoblastic leukemia in an international study of 707 cases.在一项涉及 707 例病例的国际研究中，对儿科和成人 T 细胞急性淋巴细胞白血病进行了转录组范围的亚分型。
Proc Natl Acad Sci U S A. 2022 Apr 12;119(15):e2120787119. doi: 10.1073/pnas.2120787119. Epub 2022 Apr 6.
10
Development and Carcinogenesis: Roles of GATA Factors in the Sympathoadrenal and Urogenital Systems.发育与致癌作用：GATA因子在交感肾上腺系统和泌尿生殖系统中的作用
Biomedicines. 2021 Mar 15;9(3):299. doi: 10.3390/biomedicines9030299.
本文引用的文献
1
The role of aurora A and polo-like kinases in high-risk lymphomas.极光激酶 A 和 Polo 样激酶在高危淋巴瘤中的作用。
Blood Adv. 2019 Jun 11;3(11):1778-1787. doi: 10.1182/bloodadvances.2019000232.
2
Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma.外周 T 细胞淋巴瘤分子亚群中致癌途径的遗传驱动因素。
Blood. 2019 Apr 11;133(15):1664-1676. doi: 10.1182/blood-2018-09-872549. Epub 2019 Feb 19.
3
Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma.随机 III 期研究alisertib 或研究者选择（选定的单一药物）在复发或难治性外周 T 细胞淋巴瘤患者。
J Clin Oncol. 2019 Mar 10;37(8):613-623. doi: 10.1200/JCO.18.00899. Epub 2019 Feb 1.
4
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.莫格利珠单抗对比伏立诺他治疗既往治疗的皮肤 T 细胞淋巴瘤（MAVORIC）：一项国际性、开放性标签、随机、对照的 3 期临床试验。
Lancet Oncol. 2018 Sep;19(9):1192-1204. doi: 10.1016/S1470-2045(18)30379-6. Epub 2018 Aug 9.
5
Polo-like-kinase 1 (PLK-1) and c-myc inhibition with the dual kinase-bromodomain inhibitor volasertib in aggressive lymphomas.在侵袭性淋巴瘤中使用双激酶-溴结构域抑制剂沃拉替尼抑制Polo样激酶1（PLK-1）和c-myc
Oncotarget. 2017 Dec 6;8(70):114474-114480. doi: 10.18632/oncotarget.22967. eCollection 2017 Dec 29.
6
Survival following salvage therapy for primary refractory peripheral T-cell lymphomas (PTCL).原发难治性外周 T 细胞淋巴瘤（PTCL）挽救治疗后的生存情况。
Am J Hematol. 2018 Mar;93(3):394-400. doi: 10.1002/ajh.24992. Epub 2017 Dec 18.
7
Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management.皮肤 T 细胞淋巴瘤：2017 年诊断、风险分层和治疗更新。
Am J Hematol. 2017 Oct;92(10):1085-1102. doi: 10.1002/ajh.24876.
8
A single center phase II study of ixazomib in patients with relapsed or refractory cutaneous or peripheral T-cell lymphomas.一项关于伊沙佐米治疗复发或难治性皮肤或外周T细胞淋巴瘤患者的单中心II期研究。
Am J Hematol. 2017 Dec;92(12):1287-1294. doi: 10.1002/ajh.24895. Epub 2017 Sep 25.
9
T-cell transcription factor GATA-3 is an immunophenotypic marker of acute leukemias with T-cell differentiation.T细胞转录因子GATA-3是具有T细胞分化的急性白血病的免疫表型标志物。
Hum Pathol. 2017 Jul;65:166-174. doi: 10.1016/j.humpath.2017.05.009. Epub 2017 May 24.
10
Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network.专家组对淋巴瘤诊断的影响：法国淋巴病理网络的患者研究。
J Clin Oncol. 2017 Jun 20;35(18):2008-2017. doi: 10.1200/JCO.2016.71.2083. Epub 2017 May 1.
Zotero 插件